uploads/2015/09/Graph-Part-3-09-16-20151.png

XBI’s Top Ten Small-Caps Outperform IBB’s Top Ten Small-Caps

By

Updated

XBI small-caps outperform

In the small cap space, the top ten stocks of the SPDR S&P Biotechnology ETF (XBI) outperformed the top ten stocks of the iShares Nasdaq Biotechnology ETF (IBB), with an average return of 3.39% and 2.68% respectively, for the week ending September 18, 2015.

The above graph reflects the performance of top ten small-cap stocks of IBB and XBI for the week ending September 18. The combined weight of IBB’s top ten small-cap stocks stood at 2.19%, whereas the weight of XBI’s top ten small-cap stocks stood at 11.74%.

Article continues below advertisement

ZIOPHARM Oncology rose 18.55%

ZIOPHARM Oncology (ZIOP) rose 18.55% for the week ending September 18. In a recent press release, ZIOP announced “the presentation of clinical and preclinical data from the Company’s Ad-RTS-IL-12 program in various malignancies at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference taking place September 16-19, 2015 in New York City. Ad-RTS-IL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response.” ZIOP has a weight of 0.71% in XBI’s portfolio. The stock closed at $12.59 and was trading above 20-, 50-, and 100-day moving averages. ZIOP 14-day RSI (Relative Strength Index) stood at 71, indicating that the stock might have been overbought.

Sarepta Therapeutics (SRPT) rose 11.10% after it presented data at the 2015 Morgan Stanley Global Healthcare Conference. There was a spike in the trading volume on September 17th and 18th. The week’s five-day trading average stood at ~1.58 million shares per day. SRPT closed at $39.93 and was trading above 20-, 50-, and 100-day moving averages. SRPT has a weight of 1.76% in XBI’s portfolio.

Investors can invest in these stocks indirectly through XBI. XBI’s portfolio includes stocks such as bluebird bio (BLUE), Vertex Pharmaceuticals (VRTX), and Medivation (MDVN).

 

Advertisement

More From Market Realist